Exablate Neuro™

Incisionless Brain Surgery

Neuro care

Incisionless Brain Surgery

Exablate Neuro™

MR-guided Focused Ultrasound for Essential Tremor and Tremor-Dominant Parkinson’s Disease

Incisionless brain surgery is now possible

Next Generation Neurosurgery Platform

The award winning Exablate Neuro™ delivers up to 1024 ultrasound waves to precisely heat and ablate deep brain targets with no surgical incisions or burr holes. Treatment is guided by MR imaging for patient-specific planning, real-time temperature monitoring as well as immediate confirmation of treatment outcome.

Incisionless Brain Surgery

First, low energy is applied for locating the ultrasound to the anatomic target followed by physiologic evaluation of patient response including tremor relief as well as potential side effects.

Once the target is confirmed, the energy is gradually increased to create a highly accurate and controllable lesion. The result for many patients is immediate improvement of tremor with no overnight hospital stay.


  • FDA-approved focused ultrasound treatment for Essential Tremor and Tremor-Dominant PD.
  • No craniotomy with low to no risk of infection or bleeding.
  • No implanted hardware or multiple follow up visits.
  • Quick recovery and rapid return to daily activities for patients.


MR-guided focused ultrasound (MRgFUS) can be an option for medication-refractory Essential Tremor (ET) and Tremor-Dominant Parkinson’s Disease (PD) patients who are not candidates or not willing to have invasive surgery.

Incisionless treatment

No invasive burr holes or implants.
No general anesthesia required.
Little to no risk of infection.
Minimal hospitalization.

Personalized treatment

Neurologic evaluation of patient response and potential side effects before final lesion.
Enables sub-millimeter target movement.

Tremor improvement

Immediate tremor improvement
ET tremor stably maintained at 3 years.
Improved quality of life.

Safe and effective

Real-time thermal feedback to continuously monitor patient safety and temperature at target.
Majority of adverse events in the pivotal study were minor or moderate and transient.



Download brochure here: